Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Inspire II Upper Airway Stimulation (UAS) Therapy

A surgically implanted hypoglossal nerve stimulator for the treatment of moderate to severe obstructive sleep apnea in patients who do not adequately benefit from continuous positive airway pressure therapy. 

Nucleus Hybrid L24 Implant System

An electric-acoustic hybrid cochlear implant system for adults with residual low-frequency hearing and bilateral severe to profound high-frequency sensorineural hearing loss, and who obtain limited benefit from bilateral hearing aids.

Sovaldi (Sofosbuvir)

Once-daily oral polymerase inhibitor for the treatment of hepatitis C genotypes 1, 2, 3 and 4.

Olysio (simeprevir)

A once-daily oral NS3/4A protease inhibitor for the treatment of HCV genotype 1 infection.